HC Wainwright & Co. Maintains Buy on Rallybio, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor maintains a 'Buy' rating on Rallybio (NASDAQ:RLYB) but lowers the price target from $18 to $17.
November 10, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a 'Buy' rating on Rallybio but lowers the price target from $18 to $17.
The news is directly related to Rallybio. The 'Buy' rating is maintained which is positive, but the price target is lowered which might have a negative impact. Therefore, the short term impact is neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100